Pomalidomide can enhance the immune response mediated by T cells and natural killer (NK) cells, while inhibiting the production of pro-inflammatory cytokines in monocytes.

1、 Drug name

1. Common name: Pomalidomide

2. Product Name: POMALYST ®

2、 Indications

Suitable for the treatment of multiple myeloma patients who have received at least two previous therapies (including lenalidomide and bortezomib) and have experienced disease progression within 60 days after completing the last treatment.

3、 Specifications and characteristics

Capsules, specifications include: 2mg, 4mg.

4、 Main components

Active ingredient: Pomalidomide

5、 Usage and dosage

1. The recommended starting dose is 4mg orally once daily, taken from day 1 to day 21 of a 28 day treatment cycle until disease progression. Can be used in combination with dexamethasone.

2. Usage: Swallow the whole capsule, do not open, chew or crush the capsule, take with warm water.

3. Medication time: It should be taken on an empty stomach, at least 2 hours before or after meals.

6、 Dose adjustment

1. Neutropenia: When ANC<500/μ L or febrile neutropenia occurs, treatment should be suspended and reduced to 3mg/day after recovery; If it happens again, reduce the dosage by 1mg each time.

2. Thrombocytopenia: Suspend treatment when platelet count is less than 25000/μ L, and reduce to 3mg/day after recovery to>50000/μ L; If it happens again, reduce the dosage by 1mg each time.

3. Other grade 3/4 toxicity: Suspend treatment and reduce the dose by 1mg after the toxicity is reduced to ≤ grade 2.

4. The minimum dose is 1mg, and if toxicity persists, the medication should be discontinued.

7、 Medication precautions

1. Before and after meals: It should be taken on an empty stomach, at least 2 hours before or after meals.

2. Missed service: If the missed service time does not exceed 12 hours, it can be supplemented; If it exceeds 12 hours, skip the dose and take the medication at the original time the next day. Do not double the dosage.

3. Vomiting: If vomiting occurs after taking medication, it is not recommended to take the next dose according to the original plan.

4. Other: Avoid contact with capsule contents. If skin or mucous membranes come into contact, immediately wash with soap and water or rinse with water.

8、 Medication for special populations

1. Pregnancy period: Prohibited, with risks of embryo fetal toxicity.

2. Breastfeeding period: Breastfeeding or medication should be stopped, depending on the importance of the medication to the mother.

3. Women of childbearing age: Two negative pregnancy tests are required before treatment, and two reliable contraceptive measures must be taken during treatment and within 4 weeks after discontinuation of medication.

4. Male: Condoms should be used during treatment and for 28 days after discontinuing medication, and sperm donation is not allowed.

5. Children: Safety and efficacy have not been established.

6. Elderly: No need to adjust dosage.

7. Renal insufficiency: Avoid use for patients with serum creatinine>3.0mg/dL.

8. Liver dysfunction: Avoid use for patients with serum bilirubin>2.0mg/dL and AST>3 × ULN.

9、 Adverse reactions

1. The most common adverse reactions (≥ 30%) include fatigue, neutropenia, anemia, constipation, nausea, diarrhea, difficulty breathing, upper respiratory tract infections, back pain, and fever.

2. Serious adverse reactions include: venous thromboembolism, hematological toxicity hypersensitivityreactions、 Dizziness, confusion, neuropathy, and risk of secondary malignant tumors.

10、 Contraindications

Pregnant women are prohibited from using it.

11、 Drug interactions

1. Drugs that may increase blood drug concentrations, such as CYP1A2, CYP3A, or P-gp strong inhibitors (such as ketoconazole), should be avoided in combination.

2. Drugs that may lower blood drug concentrations, such as CYP1A2, CYP3A, or P-gp strong inducers (such as rifampicin), should be avoided in combination.

3. Smoking: may reduce exposure to pomalidomide by inducing CYP1A2, affecting therapeutic efficacy.

12、 Storage method

Stored at 20 ° C-25 ° C (68 ° F-77 ° F), short-term storage is allowed within the range of 15 ° C-30 ° C (59 ° F-86 ° F).

Pomalidomideinformation